Emergent BioSolutions Inc. (NYSE:EBS) was the recipient of some unusual options trading on Monday. Stock investors purchased 4,889 put options on the stock. This represents an increase of 1,204% compared to the typical daily volume of 375 put options.
Shares of NYSE EBS opened at $61.59 on Tuesday. The stock has a market cap of $3.30 billion, a PE ratio of 19.80 and a beta of 1.26. The business has a fifty day moving average of $78.89 and a two-hundred day moving average of $92.24. Emergent BioSolutions has a 52-week low of $60.70 and a 52-week high of $137.61. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.30 and a current ratio of 3.20.
Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.56. Emergent BioSolutions had a return on equity of 26.68% and a net margin of 12.50%. Analysts predict that Emergent BioSolutions will post 6.94 earnings per share for the current year.
Large investors have recently made changes to their positions in the company. Riverview Trust Co acquired a new stake in shares of Emergent BioSolutions in the fourth quarter valued at $30,000. Baillie Gifford & Co. acquired a new stake in Emergent BioSolutions in the fourth quarter worth about $36,000. Neo Ivy Capital Management increased its position in Emergent BioSolutions by 560.7% in the fourth quarter. Neo Ivy Capital Management now owns 403 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 342 shares during the period. Arkadios Wealth Advisors acquired a new stake in Emergent BioSolutions in the fourth quarter worth about $41,000. Finally, Oakworth Capital Inc. acquired a new stake in Emergent BioSolutions in the first quarter worth about $41,000. Institutional investors own 80.23% of the company’s stock.
Several brokerages recently issued reports on EBS. Chardan Capital lowered their price target on Emergent BioSolutions from $112.00 to $92.00 and set a “buy” rating on the stock in a research note on Friday. Benchmark lowered their price target on Emergent BioSolutions from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday. Guggenheim lowered their price objective on Emergent BioSolutions from $130.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, April 14th. Finally, Wells Fargo & Company downgraded Emergent BioSolutions from an “overweight” rating to an “equal weight” rating and set a $110.00 target price for the company. in a research report on Friday, January 8th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Emergent BioSolutions currently has a consensus rating of “Buy” and a consensus target price of $103.43.
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
See Also: Retained Earnings
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.